A Multi-Center, Double-Masked, Randomized, One-Year Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle-Control in Subjects With Dry Eye Disease (DED)
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Isunakinra (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Eleven Biotherapeutics
- 28 May 2015 Status changed from recruiting to discontinued according to an Eleven Biotherapeutics media release.
- 04 Mar 2015 According to Eleven Biotherapeutics media release, status changed from not yet recruiting to recruiting.
- 26 May 2014 New trial record